Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Neuroscience›Nerve Fibers
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Nerve Fibers

Neuroscience · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed9 referencesApproximately 3 min read

Slender processes of neurons, including the axons and their glial envelopes (myelin sheath).

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 3 complete abstracts (553 words), 9 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

Slender processes of neurons, including the axons and their glial envelopes (myelin sheath). Nerve fibers conduct nerve impulses to and from the central nervous system.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Nerve Fiber; Cerebellar Mossy Fibers; Cerebellar Mossy Fiber; Mossy Fiber, Cerebellar; Mossy Fibers, Cerebellar.

Where it fits in the MeSH classification

Broader topics
Neurons
Narrower topics
Adrenergic Fibers; Autonomic Fibers, Postganglionic; Axons; Cholinergic Fibers; Nerve Fibers, Myelinated; Nerve Fibers, Unmyelinated

Related concepts

  • Neurons
  • Axons
  • Myelin Sheath
  • Central Nervous System

Research landscape

PubMed indexes 136,808 records tagged with the MeSH heading “Nerve Fibers” (counts retrieved 2026-10-29). 13,286 of them (9.7%) were published from 2020 onward, and the busiest period so far is through 1999 with 60,414 records.

Reviews account for 11,252 records (8.2%) and meta-analyses for 135. Randomized controlled trials number 380 (0.3%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 60,414 records; 2000-2009: 31,790 records; 2010-2019: 31,318 records; 2020 onward: 13,286 records60,414through 199931,7902000-200931,3182010-201913,2862020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 199960,414
2000-200931,790
2010-201931,318
2020 onward13,286
Share of records by publication typeReviews: 8.2 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.3 percentReviews8.2% (11,252)Meta-analyses0.1% (135)Randomized controlled trials0.3% (380)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 136,808 PubMed records
TypeRecordsShare
Reviews11,2528.2%
Meta-analyses1350.1%
Randomized controlled trials3800.3%

Method: PubMed query "Nerve Fibers"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in neuroscience

Neuroscience draws on tools with different strengths: cellular and animal work can manipulate circuits directly, while human imaging and electrophysiology observe the living brain at lower resolution. Small imaging studies are prone to false positives, and findings in animals do not always carry over to people. Clinical neurology and psychiatry rely on trials and cohort studies whose outcomes are often symptom scales. Check the species, the sample size, how the outcome was measured and whether results were replicated.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Myelin sheaths in the central nervous system can withstand damage and dynamically remodel
Arafa D, van de Korput J, Braaker PN, Higgins KP, Meijns NRC, Marshall-Phelps KLH, et al.
2026Research article
Design not recorded in structured metadata
9cc by
PMID 41678629 · DOI · PMC7618902
Microtubules in the axon are GDP bound but adopt a stable GTP-like expanded state
Zehr EA, Sun S, Sarbanes SL, Roll-Mecak A
2026Research article
Design not recorded in structured metadata
8cc by
PMID 41951886 · DOI · PMC13095656
Dose-Dependent Biphasic Effect of Palmitic Acid on Oligodendrocyte Function: Impacts on Viability, Differentiation, and Myelination
Palmiero A, Pipicelli L, Rosa G, Sozio C, Punziano C, Raia M, et al.
2026Research article
Design not recorded in structured metadata
6cc by
PMID 41661646 · DOI · PMC12885150

Myelin sheaths in the central nervous system can withstand damage and dynamically remodel [1]

Research article Arafa D, van de Korput J, Braaker PN, Higgins KP, Meijns NRC, Marshall-Phelps KLH, et al. · · 2026 · cited 9 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Myelin damage is a hallmark of several neurological disorders, but how it occurs remains to be fully understood.
Closing excerpt
Our data indicate that myelin swelling is a conserved feature of demyelination and that damage to myelin sheaths can resolve, opening opportunities for targeting human disease.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (125 words)

Myelin damage is a hallmark of several neurological disorders, but how it occurs remains to be fully understood. In this study, we found that early damage in zebrafish and rodent demyelination models is characterized by myelin swelling. We show, through live imaging, that myelin swelling does not always lead to myelin loss and that swellings can sometimes resolve, allowing sheaths to remodel. Increased neuronal activity during early demyelination exacerbates myelin damage, whereas reducing neuronal activity mitigates myelin swelling in both zebrafish and mice. In human multiple sclerosis tissue, myelin swelling is also dynamic and is prominent around active lesions. Our data indicate that myelin swelling is a conserved feature of demyelination and that damage to myelin sheaths can resolve, opening opportunities for targeting human disease.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41678629 · DOI · PMC7618902

Microtubules in the axon are GDP bound but adopt a stable GTP-like expanded state [2]

Research article Zehr EA, Sun S, Sarbanes SL, Roll-Mecak A · · 2026 · cited 8 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Microtubules scaffold cells, supporting signaling and cargo transport.
Closing excerpt
Our work provides molecular insights into neurogenesis and has implications for understanding microtubule stability and effector recruitment in neurons.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (146 words)

Microtubules scaffold cells, supporting signaling and cargo transport. They assemble from GTP-tubulin, which hydrolyzes to GDP-tubulin during polymerization. GTP-microtubule lattices are stable; GDP lattices depolymerize rapidly. In vitro, hydrolysis triggers lattice compaction. Lattice spacing regulates motors and microtubule-associated proteins; however, the conformation of tubulin in microtubules in cells is unknown. Here, we present the atomic-resolution cryo-electron microscopy structure of human microtubules in situ, in the axons of human cortical neurons derived from induced pluripotent stem cells (iPS cells). Our 2.7-Å-resolution reconstruction delineates bound water molecules and reveals that axonal microtubules adopt an expanded GTP-like lattice, despite being GDP bound. Using cryo-electron tomography and power spectrum analysis, we find that, unlike in axons, microtubules in undifferentiated iPS cells are compacted. Therefore, lattice expansion is part of neuronal differentiation. Our work provides molecular insights into neurogenesis and has implications for understanding microtubule stability and effector recruitment in neurons.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41951886 · DOI · PMC13095656

Dose-Dependent Biphasic Effect of Palmitic Acid on Oligodendrocyte Function: Impacts on Viability, Differentiation, and Myelination [3]

Research article Palmiero A, Pipicelli L, Rosa G, Sozio C, Punziano C, Raia M, et al. · · 2026 · cited 6 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Palmitic acid (PA), the most abundant saturated fatty acid (SFA) in humans, plays a key role in energy metabolism, membrane synthesis, and signaling.
Closing excerpt
These findings highlight the physiological relevance of low-dose PA in modulating OLs.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (282 words)

Palmitic acid (PA), the most abundant saturated fatty acid (SFA) in humans, plays a key role in energy metabolism, membrane synthesis, and signaling. Oligodendrocyte precursor cells (OPCs), which generate mature oligodendrocytes (OLs) forming the myelin sheath, are responsive to metabolic and redox signals. Despite increasing interest in lipid metabolism and mitochondrial dynamics as regulators of OPC fate, the effects of PA remain unclear. This study investigates the biphasic, dose-dependent effects of PA on OPCs using the oligodendrocyte precursor MO3.13 cell line and employs rat organotypic slice cultures to evaluate the effects of non-toxic PA doses under pathological conditions and on axonal (re)-myelination. In MO3.13 cells, high-dose PA (100 µM) induces mitochondrial fragmentation and caspase-7 activation, accompanied by reduced mitofusin-2 (MFN2) and phosphorylated dynamin-related protein 1 at Ser616 (p-DRP1), indicating altered fusion-fission balance and impaired reactive oxygen species (ROS) generation. In contrast, low-dose PA (25 µM) triggers a protective response involving nuclear factor erythroid 2-related factor 2 (Nrf2) activation and upregulation of antioxidant and lipid-regulatory genes (glutamate-cysteine ligase modifier subunit [GCLM], NAD(P)H dehydrogenase [quinone] 1 [NQO1], peroxisome proliferator-activated receptor gamma [PPARγ], and cluster of differentiation 36 [CD36]) resulting in reduced intracellular ROS and enhanced lipid mobilization. PA 25 µM promotes OPC differentiation by inhibiting migration and cell cycle progression and increasing myelin basic protein (MBP) and proteolipid protein (PLP) expression. Notably, early exposure (1 day) favors mitochondrial fusion, whereas prolonged exposure (4 days) shows a physiological shift to fission. PA 25 µM prevents neurodegeneration in hippocampal organotypic slice cultures exposed to a neuroinflammatory insult. In cerebellar organotypic slice cultures, PA 25 µM enhances axonal myelination and accelerates remyelination following lysolecithin-induced demyelination. These findings highlight the physiological relevance of low-dose PA in modulating OLs.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41661646 · DOI · PMC12885150

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Spinal cord injury: molecular mechanisms and therapeutic interventions [4]
    Hu X, Xu W, Ren Y, Wang Z, He X, Huang R, et al. · Signal Transduct Target Ther · 2023 · cited 584 times (Europe PMC)
  • Research article Regulation of axonal regeneration after mammalian spinal cord injury [5]
    Zheng B, Tuszynski MH · Nat Rev Mol Cell Biol · 2023 · cited 287 times (Europe PMC)
  • Research article Central nervous system regeneration [6]
    Varadarajan SG, Hunyara JL, Hamilton NR, Kolodkin AL, Huberman AD · Cell · 2022 · cited 237 times (Europe PMC)
  • Research article The sympathetic nervous system in development and disease [7]
    Scott-Solomon E, Boehm E, Kuruvilla R · Nat Rev Neurosci · 2021 · cited 189 times (Europe PMC)
  • Research article Periods of synchronized myelin changes shape brain function and plasticity [8]
    de Faria O, Pivonkova H, Varga B, Timmler S, Evans KA, Káradóttir RT · Nat Neurosci · 2021 · cited 181 times (Europe PMC)
  • Research article Recent progress and challenges in the treatment of spinal cord injury [9]
    Tian T, Zhang S, Yang M · Protein Cell · 2023 · cited 144 times (Europe PMC)

References

  1. Arafa D, van de Korput J, Braaker PN, Higgins KP, Meijns NRC, Marshall-Phelps KLH, et al.. Myelin sheaths in the central nervous system can withstand damage and dynamically remodel. . 2026. PMID 41678629 · DOI · PMC7618902
  2. Zehr EA, Sun S, Sarbanes SL, Roll-Mecak A. Microtubules in the axon are GDP bound but adopt a stable GTP-like expanded state. . 2026. PMID 41951886 · DOI · PMC13095656
  3. Palmiero A, Pipicelli L, Rosa G, Sozio C, Punziano C, Raia M, et al.. Dose-Dependent Biphasic Effect of Palmitic Acid on Oligodendrocyte Function: Impacts on Viability, Differentiation, and Myelination. . 2026. PMID 41661646 · DOI · PMC12885150
  4. Hu X, Xu W, Ren Y, Wang Z, He X, Huang R, et al.. Spinal cord injury: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023. PMID 37357239 · DOI · PMC10291001
  5. Zheng B, Tuszynski MH. Regulation of axonal regeneration after mammalian spinal cord injury. Nat Rev Mol Cell Biol. 2023. PMID 36604586 · DOI
  6. Varadarajan SG, Hunyara JL, Hamilton NR, Kolodkin AL, Huberman AD. Central nervous system regeneration. Cell. 2022. PMID 34995518 · DOI · PMC10896592
  7. Scott-Solomon E, Boehm E, Kuruvilla R. The sympathetic nervous system in development and disease. Nat Rev Neurosci. 2021. PMID 34599308 · DOI · PMC8530968
  8. de Faria O, Pivonkova H, Varga B, Timmler S, Evans KA, Káradóttir RT. Periods of synchronized myelin changes shape brain function and plasticity. Nat Neurosci. 2021. PMID 34711959 · DOI
  9. Tian T, Zhang S, Yang M. Recent progress and challenges in the treatment of spinal cord injury. Protein Cell. 2023. PMID 36856750 · DOI · PMC10501188

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • AxonsNeuroscience
  • NeuritesNeuroscience
  • Nerve EndingsNeuroscience
  • White MatterNeuroscience
  • NeuronsNeuroscience
  • Gray MatterNeuroscience

All 110 articles in Neuroscience →

At a glance

136,808
PubMed records on this heading
10%
published since 2020
11,252
review articles
380
randomized trials
9
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • AxonsNeuroscience
  • NeuritesNeuroscience
  • Nerve EndingsNeuroscience
  • White MatterNeuroscience
  • NeuronsNeuroscience

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support